Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06194799 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT06194799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06194799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
April 23, 2024
Completion date
May 31, 2029
Enrollment
752 (estimated)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease psychosis